Development and Characterization of Deflazacort Nanoparticles for the Treatment of Inflammatory Bowel Disease
Authors/Creators
- 1. Department of Pharmacy, School of Pharmacy and Research, People's University, Bhanpur, Bhopal
Description
Inflammatory Bowel Disease (IBD) are difficult to control and the reappearance is the most challenging issue for the
physicians. IBD includes Ulcerative colitis (UC) and Crohn's disease (CD) .There are various controlled and colon targeted
drug delivery systems available for the treatment with a limited success rate. Nanoparticles prepared by using the colon
targeted polymers such as chitosan may improve the condition of IBD due to their smaller size, unique physicochemical
properties, and targeting potential. Deflazacort is a glucocorticoid used as an anti-inflammatory, immunosuppressant and
commonly prescribed drug for the patient having IBD such as Ulcerative Colitis (UC) and Crohn's Disease (CD). The
purpose of the present study was to prepare and evaluate the potential of eudragit coated chitosan nanoparticles of
Deflazacort for the treatment of IBD by ionic gelation method. These nanoparticles were further coated with Eudragit S-100
by the solvent evaporation technique so as to prevent drug release in the stomach and small intestine. Developed
Nanoparticles were subjected to various characterization tsechniques such as FTIR, particle size, scanning electron
microscopy (SEM), drug entrapment efficiency and zeta potential. The efficiency of drug release from prepared formulation
was studied in vitro in gastrointestinal fluids of different pH. The prepared nanoparticles demonstrated the size in the nano
range. The release pattern of Deflazacort from eudragit-coated chitosan nanoparticles was observed to be pH dependent. In
acidic medium, the release rate was much slower however the drug was released quickly at pH 6.8 and 7.5. Subsequently,
stability study at various storage temperature was also done in which the prepared formulation showed improved stability.
The zeta potential of the best chitosan preparation (F2) was found to be -30.5 mV, which confirms the stability of prepared
nanosuspension. Eudragit-coated chitosan nanoparticles can be a promising carrier for colon-targeted delivery of
Deflazacort found to have high encapsulation efficiency and predetermined in vitro drug release profile.
Files
10.pdf
Additional details
References
- 1. Joshi N, Rajeshwari K. Deflazacort, J Postgrad Med. 2009;55(4):296–300. 2. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy, Drugs. 1995;50(2):317-33. 3. Patel SR, Nayak GU, Harsha KP. Deflazacort, Asian Journal of Ear, Nose & Throat. 2011; 1-12. 4. Mayyas MA, Remawi Al. Properties of chitosan nanoparticles formed using sulphate anions as crosslinking bridges. Am J Appl Sci. 2012;9:1091- 1100. 5. Zohri M, Gazori T, Mirdamadi S, Asadi A, Haririan I. Polymeric nanoparticles: Production, applications a n d a d v a n t a g e . I J N T. 2 0 0 9 ; 3 : 1 - 1 4 . 6. Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, et al. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. Int J Pharm. 2013; 440: 3-12. 7. Viscido A, Capannolo A, Latella G, Caprilli R, Frieri G. Nanotechnology in the treatment of inflammatory bowel diseases. J Crohns Colitis. 2014; 8: 903-18. 8. Pichai MVA, Ferguson LR. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel disease. World J Gastroenterol. 2012;18:2895-901. 9. Antoniou J, Liu F, Majeed H, Qi J, Yokoyama W, Zhong F. Physicochemical and morphological p r o p e r t i e s o f s i z e c o n t r o l l e d c h i t o s a n - tripolyphosphate nanoparticles. Colloids and Surfaces A: Physicochem. Engineering Aspects. Elsevier Sciences. 2015; 465:137-46. 10. Dubey R, Dubey R, Omrey P, Vyas SP, Jain SK. Development and characterization of colon specific drug delivery system bearing 5-ASA and camylofine dihydrochloride for the treatment of ulcerative colitis. J Drug Target. 2010;18(8):589–601. 11. Guan J, Cheng P, Huang SJ, Wu JM, Li ZH, You XD, et al. Optimized preparation of levofloxacin-loaded chitosan nanoparticles by ionotropic gelation. Physics Procedia. 2011; 22:163-69. 12. Kumar J, Newton AMJ. Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD). Recent Patents on Inflammation & Allergy
- Drug Discovery. 2017;11(1):41-52. 13. Gawde P, Agrawal S. Design and Characterization of Eudragit coated Chitosan Microspheres of Deflazacort for Colon Targeting. J Pharm Res. 2012;5(9):4867-4870.